Sarcopenia Pipeline Analysis 2024: FDA Approvals, Medication, Clinical Trials, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Sarcopenia pipeline constitutes 10+ key companies continuously working towards developing 10+ Sarcopenia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Sarcopenia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcopenia Market.
The Sarcopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Sarcopenia Pipeline Report:
• Sarcopenia Companies across the globe are diligently working toward developing novel Sarcopenia treatment therapies with a considerable amount of success over the years.
• Sarcopenia companies working in the treatment market are Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others, are developing therapies for the Sarcopenia treatment
• Emerging Sarcopenia therapies such as MYMD-1, OC514, and others are expected to have a significant impact on the Sarcopenia market in the coming years.
• In July 2023, Biophytis has announced that it has filed for approval from the US Food and Drug Administration (FDA) to launch SARA-31, which will be the first Phase III study in sarcopenia.
• On March 2023, MyMD Pharmaceuticals Inc. announced a study of phase 2 clinical trials for MYMD-1 600MG. The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines.
• On July 2023, Australian Catholic University announced a study of phase 4 clinical trials for Pendulum WBF-038. To evaluate the effect of 12 months of supplementation with a probiotic (probiotic plus prebiotic; 2 capsules per day) on relative change (%) in total volumetric bone density (measured using high resolution peripheral quantitative computed tomography [HR-pQCT]) of the distal tibia.

Sarcopenia Overview
Sarcopenia is a progressive, age-related condition characterized by the loss of skeletal muscle mass, strength, and function. It is a key contributor to physical frailty, reduced mobility, and diminished quality of life in older adults. While primarily associated with aging, sarcopenia can also result from chronic illnesses, physical inactivity, poor nutrition, or inflammatory conditions.
The onset of sarcopenia begins as early as the fourth decade of life, with muscle mass and strength declining more rapidly after the age of 60. Symptoms include difficulty climbing stairs, slower walking speed, and reduced ability to perform everyday tasks. In advanced cases, it increases the risk of falls, fractures, and dependency on caregivers.
Sarcopenia's underlying mechanisms include hormonal changes, mitochondrial dysfunction, reduced protein synthesis, and increased muscle degradation. Its diagnosis involves assessing muscle mass (via imaging like DEXA or MRI), muscle strength (grip strength tests), and physical performance (gait speed or chair-stand tests).
Management strategies focus on resistance and aerobic exercise, which help preserve and rebuild muscle mass. Adequate protein intake, often supplemented with amino acids like leucine, is also crucial. Emerging treatments, including pharmacological interventions targeting muscle pathways, offer hope for improving outcomes in sarcopenia patients.

Get a Free Sample PDF Report to know more about Sarcopenia Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Route of Administration
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Sarcopenia Molecule Type
Sarcopenia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Sarcopenia Pipeline Therapeutics Assessment
• Sarcopenia Assessment by Product Type
• Sarcopenia By Stage and Product Type
• Sarcopenia Assessment by Route of Administration
• Sarcopenia By Stage and Route of Administration
• Sarcopenia Assessment by Molecule Type
• Sarcopenia by Stage and Molecule Type

DelveInsight's Sarcopenia Report covers around 10+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sarcopenia product details are provided in the report. Download the Sarcopenia pipeline report to learn more about the emerging Sarcopenia therapies- https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Sarcopenia Pipeline Analysis:
The Sarcopenia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.
• Sarcopenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.

Download Sample PDF Report to know more about Sarcopenia drugs and therapies- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Sarcopenia Pipeline Drug Insight
• Coverage: Global
• Key Sarcopenia Companies: Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and others.
• Key Sarcopenia Therapies: MYMD-1, OC514, and others.
• Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies
• Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers

Request for Sample PDF Report for Sarcopenia Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Sarcopenia Report Introduction
2. Sarcopenia Executive Summary
3. Sarcopenia Overview:
4. Sarcopenia- Analytical Perspective In-depth Commercial Assessment
5. Sarcopenia Pipeline Therapeutics
6. Sarcopenia Late Stage Products (Phase II/III)
7. Sarcopenia Mid Stage Products (Phase II)
8. Sarcopenia Early Stage Products (Phase I)
9. Sarcopenia Preclinical Stage Products
10. Sarcopenia Therapeutics Assessment
11. Sarcopenia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sarcopenia Companies
14. Sarcopenia Key Products
15. Sarcopenia Unmet Needs
16 . Sarcopenia Market Drivers and Barriers
17. Sarcopenia Future Perspectives and Conclusion
18. Sarcopenia Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market
• West Syndrome Market: https://www.delveinsight.com/infographics/west-syndrome-market
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Healthcare Partner Identification Services: https://www.delveinsight.com/consulting/partner-identification-services
• Brain Cancer Market: https://www.delveinsight.com/infographics/brain-cancer-market
• Diabetic Neuropathy Market: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Prader-willi Syndrome Market: https://www.delveinsight.com/report-store/prader-willi-syndrome-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Head And Neck Cancer Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Cardiac Biomarkers Testing Devices Market: https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market
• Deep Vein Thrombosis Market: https://www.delveinsight.com/report-store/deep-vein-thrombosis-market
• Neurovascular Thrombectomy Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Acute Pancreatitis Market: https://www.delveinsight.com/infographics/acute-pancreatitis-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bacterial Skin Diseases Market: https://www.delveinsight.com/report-store/bacterial-skin-diseases-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Obstructive Pulmonary Disease Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Dyspnea Market: https://www.delveinsight.com/report-store/dyspnea-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acid Sphingomyelinase Deficiency Market: https://www.delveinsight.com/report-store/acid-sphingomyelinase-deficiency-asmd-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.